Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof, and novel crystalline forms thereof.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: Described are compounds for targeting proteases, e.g. serine proteases and their use in the diagnostic methods and methods for treatment of respiratory diseases such as cystic fibrosis. The compounds have the structure [H]—[B]-[A]; wherein [H] is a hydrophilic group, [B] is a subsite recognition group and [A] is a binding group; wherein A has the formula: —C(0)—CH2—NR1—COOR2 and wherein [B] has the structure: (i) —[CO—CH2—NR3]m-, or (ii) -[AA1-AA2]- or (iii) -(AA1-C0-CH2NR3)— or (iv) —(CO—CH2—NR3-AA1)- or (v) —(C0—CH2—NR4-AA1-AA3)-.

Abstract: A video monitoring apparatus for assessing marine diversity includes a support frame, one or more cameras mounted on the support frame for recording images, and a bait receptacle mounted on the support frame for holding bait. The bait receptacle is adapted to release bait therefrom when the support frame comes to rest on a surface.

Abstract: An antenna for a body-centric wireless communication system comprises first and second radiating structures between which is located a ground plane and a feed structure. The feed structure comprises a feed line extending between the first radiating structure and the ground plane, and a slot formed in the ground plane. A pair of shorting posts connects the first radiating structure to the ground plane. The antenna is capable of simultaneously generating in-body radiation, on-body radiation and off-body radiation in the same frequency band.

Abstract: The invention relates to methods and kits for DNA The method comprises a) contacting the sample with a plurality of metal nanoparticles functionalised with one or more RNA probes; b) forming a heteroduplex between the target DNA and RNA probe on an RNA-functionalised metal nanoparticle; c) contacting the heteroduplex of target DNA and RNA probe on the RNA-functionalised metal nanoparticle with an enzyme that cleaves RNA in a DNA-RNA heteroduplex thereby releasing the target DNA; d) repeating steps (b) and (c) until all, or substantially all, of the RNA probes on the plurality of RNA-functionalised metal nanoparticles have been cleaved from the metal nanoparticles; and e) aggregating the metal nanoparticles from which all, or substantially all, of the RNA probes have been cleaved, thereby indicating the presence of the target DNA.

Abstract: This invention relates to a process for the preparation of glycerol carbonate from the reaction of glycerol and a dialkylcarbonate, for example dimethyl carbonate, or a cyclic alkylene carbonate. More specifically, the invention relates to a process where the synthesis of glycerol carbonate is conducted in the presence of a homogeneous transesterification catalyst and involves the partial reaction of a glycerol reactant stream and a dialkyl carbonate or cyclic alkylene carbonate reactant stream and an intermediate step of alcohol by-product separation before further reaction in order to improve glycerol conversion and glycerol carbonate selectivity and yield.

Abstract: The present disclosure provides nicotinate/nicotinamide riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, and synthetic processes for the preparation thereof.

Abstract: The present invention relates to the separation of gases, and more specifically to an inventive process for the removal of carbon dioxide gas using carefully selected ionic liquid absorbents together with water in a carefully selected ratio.

Abstract: The invention provides a wellbore fluid which comprises an aqueous continuous phase and, dissolved in said aqueous continuous phase, at least one salt which exists in a liquid state at a temperature below 150° C. and which has an ammonium, phosphonium or sulfonium cation containing at least 5 carbon atoms, or a quaternised nitrogen-containing heterocyclic cation containing at least 6 carbon atoms; provided that said salt is not 2-hydroxy-N,N,N-trimethyl ethanaminium acetate; and a method of carrying out a wellbore operation, which comprises introducing into a wellbore in a clay-containing formation, a wellbore fluid according to the invention. The described salts are effective shale inhibitors.

Abstract: The invention relates to methods of preparing nicotinamide riboside and derivatives thereof.

Abstract: The invention relates to dispersions of porous solids in liquids selected from deep eutectic solvents, liquid oligomers, bulky liquids, liquid polymers, silicone oils, halogenated oils, paraffin oils or triglyceride oils, as well as to their methods of preparation. In embodiments of the invention, the porous solids are metal organic framework materials (MOFs), zeolites, covalent organic frameworks (COFs), porous inorganic materials, Mobil Compositions of Matter (MCMs) or a porous carbon. The invention also relates to the use of porous materials to form dispersions, and to assemblages of such dispersions with a gas or gases. The dispersions can exhibit high gas capacities and selectivities.

Abstract: This disclosure relates to an enhanced molecular-targeted approach that targets treatment-induced or native hypoxia present within cancers, specifically, but not limited to the treatment of metastatic prostate cancer with androgen deprivation therapy, such as anti-androgens. The disclosure describes the utility of combined inhibition of IL-8 and VEGF signalling to effect a combined therapeutic response of malignant disease, which is magnified under conditions of hypoxia. Thus, provided is a pharmaceutical combination for use in the treatment of cancer, the pharmaceutical combination comprising: a vascular endothelial growth factor (VEGF) signalling inhibitor; and an interleukin-8 (IL-8) signalling inhibitor; wherein said use comprises administration of the pharmaceutical combination to a patient receiving an anti-cancer therapy.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: This disclosure relates a composition and method for promoting the reprogramming of somatic cells to induced pluripotent stem cells, the composition comprising gelatin and laminin. The disclosure further relates to a method of preparing somatic cells for producing induced pluripotent stem cells and a method for producing induced pluripotent stem cells, and thus provides method useful for the production of expanded somatic cells and induced pluripotent stem cells for use in research and therapy.

Abstract: Described are compounds for targeting proteases, e.g. serine proteases and their use in the diagnostic methods and methods for treatment of respiratory diseases such as cystic fibrosis. The compounds have the structure [H]—[B]-[A]; wherein [H] is a hydrophilic group, [B] is a subsite recognition group and [A] is a binding group; wherein A has the formula: —C(0)—CH2—NR1—COOR2 and wherein [B] has the structure: (i) —[CO—CH2—NR3]m-, or (ii) -[AA1-AA2]- or (iii) -(AA1-C0-CH2NR3)— or (iv) —(CO—CH2—NR3-AA1)- or (v) —(C0—CH2—NR4-AA1-AA3)-.

Abstract: The present invention relates to a process for the removal of free fatty acids from glyceride oils, especially palm oil. In particular, the present invention is directed to a process wherein specific ionic liquids are utilised for removing free fatty acids contained in glyceride oils, preferably palm oil, such that a glyceride oil, having a reduced content of free fatty acids may be obtained. The invention also relates to treated glyceride oil compositions, preferably treated palm oil compositions, comprising certain ionic liquids to prevent build-up of free fatty acids in stored oil.